KyungDong Pharm signed a memorandum of understanding (MOU) with Protium Science, a specialist in contract development, analysis and manufacturing of biopharmaceuticals (CDAMO), to collaborate on next-generation biopharmaceuticals. The ceremony took place on December 5 at the company’s headquarters in Gwacheon, attended by KyungDong Pharm CEOs Ryu Ki-sung and Kim Kyung-hoon, Protium Science CEO Ahn Yong-ho and senior representatives from both companies. By combining its strengths in small-molecule medicines with Protium Science’s biopharmaceutical expertise, KyungDong Pharm aims to strengthen its position in oral biopharmaceuticals. The companies will collaborate across the development of oral antibody formulations, including cell line selection, culture and analysis. Their joint work will cover early-stage cell line selection, development of culture and purification processes, analysis and evaluation of antibody drug substances, and finished product development. Converting injectable antibody medicines into oral formulations is expected to improve patients’ quality of life and make long-term treatment, particularly for autoimmune diseases, more convenient. CEO Ryu said, “This agreement will be an important turning point in strengthening KyungDong Pharm’s capabilities in biopharmaceuticals. Through our collaboration with Protium Science, we will develop innovative medicines and deliver new value to patients.”
CEO Ahn Yong-ho then said, “Collaboration with KyungDong Pharm will be an important stepping stone to increase the competitiveness of the domestic pharmaceutical and bio industry,” and added, “We will maximize the synergy between the two companies and create a case for developing biopharmaceuticals recognized in the market.” Protium Science is a CDAMO with biopharmaceutical research, development, and production capabilities, providing services ranging from the initial stage of biopharmaceutical development to commercial production. The company, together with Protium Science, plans to carry out product development in three stages from 2024 to 2026, sequentially carrying out detailed research and development goals such as ▲ research and supply of cell lines for oral formulation development ▲ establishment of culture and purification processes ▲ quality analysis of antibody raw materials and finished pharmaceuticals. The biopharmaceutical market is growing at an average annual growth rate of more than 10% worldwide, and protein treatments and antibody treatments are particularly important. This collaboration with Protium Science is expected to contribute to increasing global competitiveness and revitalizing the domestic biopharmaceutical ecosystem in response to these market changes.